Vivani Medical, Inc. (VANI) stock
VANINasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
$1.05+0.03 (+2.94%)
Close on Nov 17, 2026Market cap $94.71MP/E –Yield –
Vivani Medical r&d expenses
Research and development expenses are spending on new products and technology.
Vivani Medical's R&D Expenses for the twelve months ending Jun 30, 2026 was $18.00M, up 2.9% year over year. For fiscal 2025 it was $18.13M, up 15.1% from the year before. Over ten years it grew 19.6% a year on average. The highest annual figure on record is $18.13M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.13M | +15.1% |
| FY2024 | Dec 31, 2024 | $15.75M | -7.2% |
| FY2023 | Dec 31, 2023 | $16.97M | +19.8% |
| FY2022 | Dec 31, 2022 | $14.17M | +28.8% |
| FY2021 | Dec 31, 2021 | $11.00M | +127.5% |
| FY2020 | Dec 31, 2020 | $4.84M | -63.2% |
| FY2019 | Dec 31, 2019 | $13.14M | +31.4% |
| FY2018 | Dec 31, 2018 | $10.01M | +26.8% |
| FY2017 | Dec 31, 2017 | $7.89M | +47.6% |
| FY2016 | Dec 31, 2016 | $5.35M | +76.1% |
| FY2015 | Dec 31, 2015 | $3.04M | -39.8% |
| FY2014 | Dec 31, 2014 | $5.04M | +55.2% |
| FY2013 | Dec 31, 2013 | $3.25M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $4.46M | -6.4% |
| Q1 FY2026 | Mar 31, 2026 | $4.39M | +4.1% |
| Q4 FY2025 | Dec 31, 2025 | $4.63M | +7.6% |
| Q3 FY2025 | Sep 30, 2025 | $4.52M | +7.5% |
| Q2 FY2025 | Jun 30, 2025 | $4.76M | +35.5% |
| Q1 FY2025 | Mar 31, 2025 | $4.22M | +13.2% |
| Q4 FY2024 | Dec 31, 2024 | $4.30M | -8.6% |
| Q3 FY2024 | Sep 30, 2024 | $4.20M | -5.4% |
| Q2 FY2024 | Jun 30, 2024 | $3.51M | -9.1% |
| Q1 FY2024 | Mar 31, 2024 | $3.73M | -5.8% |
| Q4 FY2023 | Dec 31, 2023 | $4.71M | +6.3% |
| Q3 FY2023 | Sep 30, 2023 | $4.44M | +15.1% |
| Q2 FY2023 | Jun 30, 2023 | $3.86M | +20.6% |
| Q1 FY2023 | Mar 31, 2023 | $3.96M | +47.6% |
| Q4 FY2022 | Dec 31, 2022 | $4.43M | +48.8% |
| Q3 FY2022 | Sep 30, 2022 | $3.86M | +34.6% |
| Q2 FY2022 | Jun 30, 2022 | $3.20M | +360.9% |
| Q1 FY2022 | Mar 31, 2022 | $2.68M | +702.1% |
| Q4 FY2021 | Dec 31, 2021 | $2.98M | +757.3% |
| Q3 FY2021 | Sep 30, 2021 | $2.87M | +928.0% |
| Q2 FY2021 | Jun 30, 2021 | $695.00K | +115.2% |
| Q1 FY2021 | Mar 31, 2021 | $334.00K | -91.4% |
| Q4 FY2020 | Dec 31, 2020 | $347.00K | -91.6% |
| Q3 FY2020 | Sep 30, 2020 | $279.00K | -91.7% |
| Q2 FY2020 | Jun 30, 2020 | $323.00K | -90.6% |
| Q1 FY2020 | Mar 31, 2020 | $3.89M | +78.1% |
| Q4 FY2019 | Dec 31, 2019 | $4.15M | +70.0% |
| Q3 FY2019 | Sep 30, 2019 | $3.38M | +26.5% |
| Q2 FY2019 | Jun 30, 2019 | $3.44M | +41.9% |
| Q1 FY2019 | Mar 31, 2019 | $2.18M | -11.8% |
| Q4 FY2018 | Dec 31, 2018 | $2.44M | +7.4% |
| Q3 FY2018 | Sep 30, 2018 | $2.67M | +46.3% |
| Q2 FY2018 | Jun 30, 2018 | $2.42M | +24.3% |
| Q1 FY2018 | Mar 31, 2018 | $2.47M | +33.9% |
| Q4 FY2017 | Dec 31, 2017 | $2.27M | +9.1% |
| Q3 FY2017 | Sep 30, 2017 | $1.83M | +15.0% |
| Q2 FY2017 | Jun 30, 2017 | $1.95M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.85M | – |
| Q4 FY2016 | Dec 31, 2016 | $2.08M | – |
| Q3 FY2016 | Sep 30, 2016 | $1.59M | – |
See a number that looks wrong?